

0300

Attorney Ref: 356A PCT/USC1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#4

Applicants: Cerasoli
Serial No.: 10/087,286
Filed : March 1, 2002
For : *Expression of Proteins for Treating Asthma
via Ligand Mediated Activation of their
Encoding Genes*



Art Unit: 1632

Examiner: —

Handwritten initials

U.S. Patent and Trademark Office
Box Sequence, P.O. Box 2327
Arlington, VA 22202

May 21, 2002

**Response to Notice to Comply with Requirements for Patent Applications containing
Nucleotide Sequence and/or Amino Acid Sequence Disclosures**

Applicants submit a Sequence Listing for the above referenced application under 37 CFR 1.821 through 1.825 in response to a Notice to Comply mailed March 29, 2002. The deadline for responding to the notice is May 29, 2002 and thus this response is deemed timely filed. Pursuant to the duty to submit DNA and amino acid sequence in computer readable form, this affirms that to the best of my knowledge and belief, the sequence listing information recorded in computer readable form is identical to the written sequence listing. In accordance with 37 CFR §1.821(a), I hereby state that the sequences contained in this Sequence Listing are supported in the application as filed. The paper copy and the computer readable copy of the amended Sequence Listing contain no new matter.

Amendment

Please amend the application to include the Sequence Listing between the specification and the claims. Also, please amend the specification to include Sequence ID numbers. These amendments do not change the meaning of the disclosure, whether by removal of any of the disclosure or by introduction of any new matter. A clean version of the amended specification is provided as Attachment A followed by a marked version as Attachment B.

No additional costs are believed to be due in connection with this amendment. However, should any such fees be due, charge any deficiency or credit any overpayment to our Deposit Account No. 01-2315. A duplicate copy of this letter is enclosed. If there are any questions about this request, the Examiner is invited to call the undersigned attorney at the number provided.

Respectfully submitted,

David L. Bernstein
David L. Bernstein, Reg No. 31,235
ARIAD Pharmaceuticals, Inc.
26 Landsdowne Street
Cambridge, MA 02139
Telephone: 617-494-0400 Ext. 266
Facsimile: 617-494-020

I hereby certify that this paper is being deposited with the United States Postal Service via First Class Mail under 37 CFR 1.08 on the date indicated above and is addressed to USPTO; Box Sequence, P.O. Box 2327; Arlington, VA 22202
Date May 21, 2002 Signed Sue Wilson
Sue Wilson